Patents by Inventor Peter Francis Joseph O'Hare
Peter Francis Joseph O'Hare has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040197346Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: ApplicationFiled: September 3, 2003Publication date: October 7, 2004Applicant: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20040171044Abstract: This application provides aggregated compositions comprising VP22 protein, or a polypeptide with the transport function of VP22, and oligonucleotides or polynucleotides. Such aggregates so produced can be useful for delivery of substances such as nucleic acids and/or peptides or proteins into cells.Type: ApplicationFiled: December 2, 2003Publication date: September 2, 2004Inventors: Peter Francis Joseph O'Hare, Nadia Michelle Normand
-
Publication number: 20040142900Abstract: This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.Type: ApplicationFiled: February 26, 2004Publication date: July 22, 2004Applicant: Phogen LimitedInventors: Peter Francis Joseph O'Hare, Nadia Michelle Normand, Neil Douglas Brewis, Anne Phelan
-
Patent number: 6734167Abstract: This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.Type: GrantFiled: December 20, 2000Date of Patent: May 11, 2004Assignee: Phogen LimitedInventors: Peter Francis Joseph O'Hare, Nadia Michelle Normand, Neil Douglas Brewis, Anne Phelan
-
Publication number: 20030219859Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.Type: ApplicationFiled: September 27, 2002Publication date: November 27, 2003Applicant: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6521455Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.Type: GrantFiled: January 31, 2001Date of Patent: February 18, 2003Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020155988Abstract: This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.Type: ApplicationFiled: December 20, 2000Publication date: October 24, 2002Inventors: Peter Francis Joseph O'Hare, Nadia Michelle Normand, Neil Douglas Brewis, Anne Phelan
-
Publication number: 20020142960Abstract: Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells.Type: ApplicationFiled: September 7, 2001Publication date: October 3, 2002Applicant: Phogen LimitedInventors: Peter Francis Joseph O'Hare, Neil Douglas Brewis, Nadia Michelle Normand, Kavitha Renga Sunassee
-
Publication number: 20020106378Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: ApplicationFiled: March 5, 2001Publication date: August 8, 2002Inventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020064534Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: ApplicationFiled: January 22, 2002Publication date: May 30, 2002Applicant: Phogen LimitedInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20020039765Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.Type: ApplicationFiled: January 31, 2001Publication date: April 4, 2002Inventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6342229Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: GrantFiled: August 2, 1999Date of Patent: January 29, 2002Assignee: Phogen, LimitedInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Publication number: 20010048928Abstract: Herpesviral particle preparations, e.g. a preparation of herpesviral particles isolated from the cell culture in which such particles were produced, can have at least part of the VP22 tegument protein present in the form of a recombinant mutant form of VP22, e.g. as a recombinant fusion polypeptide comprising a VP22-active sequence and a non-VP22 peptide or polypeptide sequence such as a fluorescent GFP sequence: corresponding DNA preparations are described. The use of virus particles containing fluorescent fusion protein to detect the progress of cell infection by virus and to screen for neutralising antibody or inhibitors of infection is also described. Vaccine uses of modified herpesvirus particles are described.Type: ApplicationFiled: August 2, 1999Publication date: December 6, 2001Inventors: PETER FRANCIS JOSEPH O'HARE, GILLIAN DAPHNE ELLIOTT
-
Patent number: 6251398Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.Type: GrantFiled: September 13, 1999Date of Patent: June 26, 2001Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6184038Abstract: The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.Type: GrantFiled: January 26, 1998Date of Patent: February 6, 2001Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 6017735Abstract: Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.Type: GrantFiled: January 22, 1998Date of Patent: January 25, 2000Assignee: Marie Curie Cancer CareInventors: Peter Francis Joseph O'Hare, Gillian Daphne Elliott
-
Patent number: 5650488Abstract: A polypeptide which inhibits the replication of Herpes Simplex Virus. The polypeptide contains the amino acid sequence 360-367 of the Herpes Simplex Virus protein Vmw 65 as shown in Sequence ID No. 1.Type: GrantFiled: February 16, 1994Date of Patent: July 22, 1997Assignee: British Technology Group LimitedInventor: Peter Francis Joseph O'Hare